PRME (Prime Medicine) PensionAndRetirementBenefit : $0.00 Mil (As of Mar. 2025)

View and export this data going back to 2022. Start your Free Trial

What is Prime Medicine PensionAndRetirementBenefit?

Prime Medicine's PensionAndRetirementBenefit for the quarter that ended in Mar. 2025 was $0.00 Mil.

Prime Medicine PensionAndRetirementBenefit Historical Data

The historical data trend for Prime Medicine's PensionAndRetirementBenefit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prime Medicine PensionAndRetirementBenefit Chart

Prime Medicine Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

PensionAndRetirementBenefit

Prime Medicine Quarterly Data
	Dec19	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
PensionAndRetirementBenefit	Get a 7-Day Free Trial												-	-	-	-	-

Prime Medicine PensionAndRetirementBenefit Calculation

PensionAndRetirementBenefit is the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.

Prime Medicine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prime Medicine Inc (NAS:PRME) » Definitions » PensionAndRetirementBenefit

Comparable Companies

Traded in Other Exchanges

N/A

Address

60 First Street, Cambridge, MA, USA, 02141

Website

https://www.primemedicine.com

Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.

Executives

Ann L. Lee	officer: Chief Technical Officer	400 DEXTER AVENUE NORTH, SUITE 1200, SEATTLE WA 98109
Richard Brudnick	officer: Chief Business Officer	BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Robert Nelsen	director, 10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners X, Llc	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Gv 2019 Gp, L.l.c.	10 percent owner	1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
Jeffrey D Marrazzo	director	3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Gv 2021 Gp, L.l.c.	10 percent owner	1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
2019, L.p. Gv	10 percent owner	1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
Gv 2019 Gp, L.p.	10 percent owner	1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
Gv 2021 Gp, L.p.	10 percent owner	1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
2021, L.p. Gv	10 percent owner	1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Alphabet Inc.	10 percent owner	1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Thomas Cahill	director	PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139
Steven Gillis	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
David P Schenkein	director	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139